Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662516 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects
A Phase 1 study of Healthy Females, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03662516 is a Phase 1 study of Healthy Females that has completed, run by Pfizer. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03662516, a Phase 1 study of Healthy Females, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, 2 way crossover, open-label study of the effect of multiple-dose PF 04965842 on single-dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences. A total of 16 healthy female subjects (8 in each treatment sequence) will be enrolled in the study. Each treatment sequence will consist of 2 periods.
Conditions Studied
Interventions
- DRUG PF-04965842
- DRUG Ethinyl estradiol (EE) and levonorgestrel (LN)
Study Locations (1)
Connecticut
- Pfizer New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2019-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03662516
The ClinicalTrials.gov registry entry for NCT03662516 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Females appearing as the primary indexed condition, and to 2 interventions - of which PF-04965842 is the first listed.
NCT03662516 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03662516 about?
NCT03662516 is a clinical study titled "A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects". This is a Phase 1, randomized, 2 way crossover, open-label study of the effect of multiple-dose PF 04965842 on single-dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences. A total of 16 healthy female subjects (8 in each treatment sequence) will be enrolle...
What is the current status of trial NCT03662516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-09-26. Estimated completion is 2019-01-19.
What conditions does trial NCT03662516 study?
This clinical trial studies the following conditions: Healthy Females.
What interventions are being tested in trial NCT03662516?
The interventions under investigation include: PF-04965842 (DRUG), Ethinyl estradiol (EE) and levonorgestrel (LN) (DRUG).
Who is sponsoring clinical trial NCT03662516?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03662516 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Females
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.